Aclaris Therapeutics (NASDAQ:ACRS) Sees Strong Trading Volume
Aclaris Therapeutics (NASDAQ:ACRS) Sees Strong Trading Volume
Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Rating) shares saw an uptick in trading volume on Friday . 758,008 shares were traded during trading, an increase of 107% from the previous session's volume of 366,400 shares.The stock last traded at $17.30 and had previously closed at $16.82.
Aclaris治疗公司(纳斯达克代码：ACRS-GET评级)的股票周五成交量上升。盘中成交量为758,008股，较前一交易日的366,400股增加107%。该股最新报17.30美元，此前收盘报16.82美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
A number of brokerages recently commented on ACRS. StockNews.com began coverage on Aclaris Therapeutics in a research note on Wednesday, October 12th. They set a "sell" rating for the company. BTIG Research began coverage on Aclaris Therapeutics in a research note on Thursday, October 6th. They set a "buy" rating and a $32.00 price objective for the company. Stifel Nicolaus began coverage on Aclaris Therapeutics in a report on Tuesday, December 13th. They set a "buy" rating and a $29.00 target price on the stock. SVB Leerink reiterated an "outperform" rating on shares of Aclaris Therapeutics in a report on Tuesday, November 8th. Finally, The Goldman Sachs Group began coverage on Aclaris Therapeutics in a report on Thursday, December 1st. They set a "buy" rating and a $25.00 target price on the stock. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, Aclaris Therapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $28.67.
多家券商近日对ACRS发表评论。StockNews.com在10月12日星期三的一份研究报告中开始报道Aclaris治疗公司。他们为该公司设定了“卖出”评级。BTIG研究在10月6日星期四的一份研究报告中开始报道Aclaris治疗公司。他们为该公司设定了“买入”评级和32.00美元的目标价。Stifel Nicolaus在12月13日星期二的一份报告中开始报道Aclaris治疗公司。他们为该股设定了“买入”评级和29.00美元的目标价。SVB Leerink在11月8日(星期二)的一份报告中重申了对Aclaris治疗公司股票的“跑赢大盘”评级。最后，高盛在12月1日星期四的一份报告中开始对Aclaris治疗公司进行报道。他们为该股设定了“买入”评级和25.00美元的目标价。一名投资分析师对该股的评级为卖出，六名分析师对该公司股票的评级为买入。根据MarketBeat.com的数据，Aclaris治疗公司目前的平均评级为“中等买入”，共识目标价为28.67美元。
Aclaris Therapeutics Stock Performance
Aclaris Treateutics股票表现
The company has a fifty day simple moving average of $16.26 and a two-hundred day simple moving average of $16.04.
该公司的50日简单移动均线切入位16.26美元，200日简单移动均线切入位16.04美元。
Insider Activity
内幕活动
In other news, insider Joseph Monahan sold 5,000 shares of the business's stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $15.88, for a total value of $79,400.00. Following the sale, the insider now directly owns 96,386 shares in the company, valued at $1,530,609.68. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, Director Neal Walker sold 25,000 shares of Aclaris Therapeutics stock in a transaction dated Tuesday, January 3rd. The stock was sold at an average price of $15.25, for a total value of $381,250.00. Following the sale, the director now owns 1,220,763 shares of the company's stock, valued at $18,616,635.75. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Joseph Monahan sold 5,000 shares of Aclaris Therapeutics stock in a transaction dated Thursday, December 15th. The shares were sold at an average price of $15.88, for a total value of $79,400.00. Following the completion of the sale, the insider now directly owns 96,386 shares in the company, valued at approximately $1,530,609.68. The disclosure for this sale can be found here. Corporate insiders own 6.70% of the company's stock.
在其他新闻方面，内部人士约瑟夫·莫纳汉在12月15日星期四的一笔交易中出售了5000股该公司股票。这只股票的平均售价为15.88美元，总价值为79,400.00美元。出售后，这位内部人士现在直接拥有该公司96,386股，价值1,530,609.68美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过美国证券交易委员会网站。相关新闻，董事尼尔·沃克在一笔日期为1月3日(星期二)的交易中出售了25,000股Aclaris治疗公司的股票。股票以15.25美元的平均价格出售，总价值为381,250.00美元。交易完成后，董事现在拥有1220,763股公司股票，价值18,616,635.75美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可通过此超链接。此外，内部人士约瑟夫·莫纳汉在12月15日星期四的交易中出售了5,000股Aclaris治疗公司的股票。这些股票的平均价格为15.88美元，总价值为79,400.00美元。出售完成后，该内部人士现在直接拥有该公司96,386股，价值约1,530,609.68美元。关于这次销售的披露可以找到这里。公司内部人士持有该公司6.70%的股份。
Institutional Trading of Aclaris Therapeutics
Aclaris Treeutics的机构交易
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Strs Ohio increased its position in Aclaris Therapeutics by 82.9% during the fourth quarter. Strs Ohio now owns 36,400 shares of the biotechnology company's stock worth $573,000 after buying an additional 16,500 shares during the last quarter. Bank of New York Mellon Corp increased its position in Aclaris Therapeutics by 15.7% during the third quarter. Bank of New York Mellon Corp now owns 233,882 shares of the biotechnology company's stock worth $3,682,000 after buying an additional 31,683 shares during the last quarter. Teachers Retirement System of The State of Kentucky acquired a new position in Aclaris Therapeutics during the third quarter worth approximately $850,000. California State Teachers Retirement System increased its position in Aclaris Therapeutics by 5.8% during the third quarter. California State Teachers Retirement System now owns 65,616 shares of the biotechnology company's stock worth $1,033,000 after buying an additional 3,618 shares during the last quarter. Finally, Balyasny Asset Management LLC acquired a new position in Aclaris Therapeutics during the third quarter worth approximately $1,670,000. Institutional investors and hedge funds own 95.33% of the company's stock.
一些对冲基金和其他机构投资者最近调整了对该股的持有量。第四季度，俄亥俄州STRS将其在Aclaris治疗公司的地位增加了82.9%。STR俄亥俄州现在拥有这家生物技术公司36,400股票，价值573,000美元，在上个季度又购买了16,500股票。纽约梅隆银行在第三季度将其在Aclaris治疗公司的头寸增加了15.7%。纽约梅隆银行(Bank Of New York Mellon Corp)目前拥有233,882股这家生物技术公司的股票，价值3,682,000美元，此前该公司在上个季度又购买了31,683股。肯塔基州教师退休系统在第三季度获得了Aclaris治疗公司的一个新职位，价值约85万美元。加利福尼亚州教师退休系统在第三季度将其在Aclaris治疗公司的职位增加了5.8%。加州教师退休系统现在拥有这家生物技术公司65,616股股票，价值1,033,000美元，此前在上个季度又购买了3,618股。最后，Balyasny Asset Management LLC在第三季度收购了Aclaris治疗公司的一个新头寸，价值约167万美元。机构投资者和对冲基金持有该公司95.33%的股票。
Aclaris Therapeutics Company Profile
Aclaris治疗公司简介
(Get Rating)
(获取评级)
Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.
Aclaris治疗公司经营着一家临床阶段的生物制药公司，在美国开发治疗免疫性炎症性疾病的新型候选药物。它通过两个部门运作：治疗和合同研究。治疗部门参与确定和开发创新疗法，以解决免疫炎症性疾病的重大未得到满足的需求。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Aclaris Therapeutics (ACRS)
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
- PCE Indicates Slowdown In Spending, Economy Weakens
- Microsoft's Comeback Is Now Underway
- 免费获取StockNews.com关于Aclaris治疗公司(ACRS)的研究报告
- 利用这些铁路股票实现增长和收入
- ASML预计今年芯片需求回升，提振销售观点
- KLA公司：在动荡不安的半市场中站稳脚跟
- PCE表明支出放缓，经济疲软
- 微软的卷土重来正在进行中
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Aclaris治疗日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Aclaris治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。